MYHEP + MYDEKLA

                                      MYHEP + MYDEKLA

PRODUCT DETAILS

Brand Name : Myhep + Mydekla

Active components : Sofosbuvir, Daclatasvir

Strength of the components : 400mg & 60mg respectively

Manufactured by : Mylan Pharmaceuticals

Category : Anti-viral drug

DESCRIPTION

Myhep + Mydekla tablets are hostile to viral medicine Myhep + Mydekla tablets are single measurements treatment, it is a doctor prescribed medication utilized by the patients just under the information of restorative expert who are all around rehearsed Daclatasvir isn't utilized alone, for better activity it ought to be joined with Sofosbuvir tablet. In some condition Myhep + Mydekla is joined with ribavirin, a hostile to viral pharmaceutical utilized as a part of decompensated (Child Pugh B or C) cirrhosis

PRESCRIBED FOR

The primary sign of Myhep + Mydekla is; This mix tablets are utilized to treat the constant hepatitis C viral disease caused by genotype I or III The significant restriction happened while utilizing Myhep + Mydekla tablets are lessening of steady virological reaction rate in hepatitis C genotype I or III contaminated patients.

PHARMACOLOGY

The activity of Myhep + Mydekla tablets are occurred by involving in some mechanism;

SOFOSBUVIR

Sofosbuvir Myhep + Mydekla containing sofosbuvir has hostile to hepaciviral movement, which is specifically acting medication displays its activity by disallowing NS5B RNA dependent RNA polymerase protein; fundamental for Myhep + Mydekla hepatitis viral duplication. Sofosbuvir is processed to frame uridine triphosphate, a fundamental dynamic metabolite which uncovered a hostile to viral action. The mixture of this dynamic metabolite into hepatitis viral RNA with the assistance of NS5B polymerase and causes viral chain cessation

DACLATASVIR

Daclatasvir containing Daclatasvir Myhep + Mydekla removes hostile to viral action by restricting NS5A protein which is needful in viral generation and virion collection

DOSAGE

Myhep + Mydekla tablets are given with or without food, in the condition of chronic hepatitis C viral infection originated by genotype I or III Myhep + Mydekla is single dose therapy

Dosage regimens

Daclatasvir normally is not used alone treatment, it is combined with Sofosbuvir The suggested dosage of Myhep + Mydekla is one tablet should be taken as a single dose If Sofosbuvir is discontinued, Daclatasvir also get stopped Genotype I Patient suffered without cirrhosis or with compensated cirrhosis: The recommended usual dosage of Myhep + Mydekla is one tablet should be taken as a single dose with or without food In decompensated cirrhosis patients: Myhep + Mydekla should be altogether with ribavirin as a single dose

PHARMACOKINETICS

Absorption :

The maximum plasma concentration of Daclatasvir tablets occurs within 2 hours The mean bioavailability of Daclatasvir is 67% The maximum plasma concentration of Sofosbuvir tablets occurs within the range of 0.5 to 2 hours relatively. The nourishment won't makes any variety in retention of Myhep + Mydekla tablets, might be taken with or without sustenance

Distribution :

Volume of distribution in Daclatasvir tablet is 47L Daclatasvir bounds to human plasma protein nearly 99% Blood to plasma ratio of Sofosbuvir is relatively 0.7 The Sofosbuvir bounds to human plasma protein nearly 61 to 65%

Metabolism :

Sofosbuvir Myhep + Mydekla metabolized in liver and formed as dynamic metabolite uridine triphosphate, metabolism experienced with the assistance of cathepsin A or carboxylesterase 1 Daclatasvir digestion happened with the assistance of CYP3A4

Elimination :

Nearly 88% of Daclatasvir is eliminated via feces; 53% as parent form; 6.6% eliminated through urine. Sofosbuvir metabolites are excreted through 80% in urine, 14% in feces & 2.5% in exhaled air The terminal half life period of Sofosbuvir is reaches at 0.51 hours; Daclatasvir half life period is 12 to 15 hours

MISSED DOSE

Both Myhep + Mydekla tablets are single dosage treatment, if tolerant neglects to take the measurement of these tablets, must counsel the doctor and take the measurement inside the time according to the direction given by therapeutic expert Generally the missed measurement ought to be skipped and take after the standard dosing plan

PRECAUTIONS

While taking Myhep + Mydekla tablets, with CYP3A solid inducers causes loss of remedial reaction of Myhep + Mydekla tablets. Stay away from this accompanying to diminish the unfriendly impacts Myhep + Mydekla causes genuine bradycardia while simultaneous use with amiodarone, to keep this condition some elective solution is given or ends the amiodarone if conceivable. Insight the patients about the introduction of bradycardia amid the treatment Utilizing Myhep + Mydekla with ribavirin, ought not be prescribed in pregnancy condition as a result of creating fetal harm because of ribavirin

CONTRAINDICATION

A few contraindications happens while utilizing Myhep + Mydekla tablets In decompensated cirrhosis, joins with ribavirin contraindicated in pregnancy condition Some anaphylactic response happens if patients are contraindicated to the segments show in Myhep + Mydekla

SIDE EFFECTS

The most common side effects occurred during the therapy;
Headache, Loss of appetite, Irritability, Neutropenia, Anemia, Chills, Influenza like symptoms, Pyrexia, Myalgia, Pancytopenia, Fatigue, Nausea, Diarrhea, Elevation of lipase, Cardiac problems like symptomatic bradycardia , Insomnia, Pruritus, Asthenia, Rashes, on the grounds that almost 99% of medication limited to human plasma protein .

OVERDOSAGE 

The over dose of Myhep + Mydekla tablets are happened because of missed measurement , if once finished dose happens the patients must be observed oftentimes for support of harmfulness and give wellbeing measures Hemodialysis is a technique used to take out the part from body, sofosbuvir evacuates with partition coefficient of 54% though Daclatasvir is hazardous

Contact Details

Phone :+91-9987711567

Email :applepharmaceutical@gmail.com

Email :info@myapplepharma.com